Dog Vaccine Market Size - By Vaccine Type (Live Attenuated, Inactivated, Recombinant), Disease Type (Canine Distemper, CIRDC, Leptospirosis, Parvovirus, Rabies), Route of Administration (Injectable, Intranasal, Oral), End-use & Forecast, 2024 – 2032

Dog Vaccine Market Size

Dog Vaccine Market size was valued at USD 1.8 billion in 2023 and is estimated to grow at 5.8% CAGR from 2024 to 2032. The expansion of this market is driven by increased awareness of pet health coupled with rising incidences of canine diseases such as rabies, parvovirus, and distemper and other diseases which emphasize the need for vaccinations. Also, the rising ownership among millennials and their emphasis on preventive healthcare for dogs are expected to significantly propel the vaccine market.
 

According to the National Pet Owners Survey conducted by the American Pet Products Association, Inc. in 2023-2024, millennials accounted for the largest share of pet ownership at 33%. Similarly, an article published by Women's Health (Hearst UK) in May 2023 highlighted a survey revealing that 63% of millennials are investing more in their dogs than themselves.
 

Dog vaccine is a biological preparation that helps protect dogs from various diseases by stimulating their immune system to recognize and fight against specific pathogens.  Vaccines contain antigens that mimic disease-causing organisms, triggering an immune response without causing the disease. This prepares the dog's immune system to recognize and respond to future infections, reducing the risk of serious illness or death.
 

Dog Vaccine Market Trends

Government initiatives for animal healthcare such as subsidized vaccination programs and public awareness campaigns to address the infection burden propel the need for animal vaccines. These initiatives encouraged higher vaccination rates and fostered a healthier pet population.
 

• For instance, a collaborative effort by the Ministries of Health, Fisheries & Livestock, Local Government, Rural Development & Cooperative, and Education have led to extensive mass dog vaccination programs, post-exposure prophylaxis for bite victims, and nationwide awareness campaigns. These inter-sector collaborations aim to address the need for preventive vaccinations in response to the rising incidence of diseases among dogs. About 2.25 million rabies vaccine doses were used to vaccinate dogs across all 64 districts, covering 81.57% by June 2022. Thus, the growing government support towards mass vaccination surged the demand for vaccines, thereby boosting the dog vaccine market growth.
   

Moreover, the growing trend of pet humanization, favorable pet insurance policies, advancements in animal health treatment, accelerated research activities, strategic expansions by key players, and increasing vaccine approvals are further driving market demand.
 

Dog Vaccine Market Analysis

Based on the vaccine type, the market is categorized into live attenuated, inactivated, recombinant, and other vaccine types. The live attenuated segment is set to lead the market, accounting for the largest revenue of USD 800.4 million, anticipating its dominance throughout the forecast period with a significant growth rate.
 

• Live attenuated vaccines use weakened forms of the pathogen stimulating a robust immune response without causing the disease. This results in effective and durable protection against various canine diseases, thereby witnessing to be the preferred choice.
   
• Also, these vaccines often require fewer doses, making them more convenient for pet owners and veterinarians. Their ability to induce both cellular and humoral immunity further enhances their effectiveness. Therefore, as a result, they are widely preferred and trusted in the veterinary community, contributing to their dominance in the market.
   

Based on disease type, the dog vaccine market is classified into canine distemper, canine infectious respiratory disease complex (CIRDC), canine parvovirus, canine leptospirosis, canine lyme disease, infectious canine hepatitis, canine rabies, and other disease types. The canine parvovirus segment holds the largest market share of 25.3% in 2023.
 

• Canine parvovirus dominance was attributed to its high contagiousness and severe impact on canine health. Parvovirus is estimated to afflict over 330,000 puppies annually, with as many as 91% facing mortality if untreated. This virus, particularly dangerous for puppies, leads to severe gastrointestinal disorders and dehydration. Therefore, the high mortality rate and rapid spread of parvovirus create a significant demand for effective vaccination.
   
• Moreover, introduction of new vaccines along with awareness pertaining to parvovirus among owners will spur the segment growth. For instance, Elanco Animal Health Incorporated launched a comprehensive educational campaign, designated as the inaugural National Parvo Awareness Day, to raise awareness about the severe and frequently fatal puppy disease. As a component of this campaign, Elanco introduces "Parvo is Poop," an engaging initiative that elucidates the virus's transmission, symptoms, and innovative treatment for canine parvovirus (parvo). This initiative aimed to spread awareness to address the challenges posed by parvovirus and enhance the dog's health globally.
   

Based on route of administration, the dog vaccine market is segmented into intranasal, injectable, and oral. The injectable segment is expected to exhibit CAGR of 5.7% during the analysis period.
 

• The injectable segment dominates the dog vaccine industry due to its ability to ensure precise dosage and reliable administration. Veterinarians and pet owners prefer injectable vaccines for their effectiveness in delivering consistent immune responses.
   
• For instance, in March 2021, MSD Animal Health launched Nobivac Respira, a single-dose injectable vaccine that offers extended protection against Bordetella bronchiseptica. Therefore, the trust and familiarity veterinarians have with injectable vaccines reinforce their widespread use and preference in preventing canine diseases, thereby augmenting the market growth.
   

Based on the end-use, the dog vaccine market is segmented into veterinary hospitals, veterinary clinics, and research institutes. The veterinary hospitals segment is projected to reach USD 1.3 billion by end of 2032.
 

• Veterinary hospitals offer comprehensive medical services including vaccinations, making them a preferred choice for pet owners seeking preventive care for their dogs. Also, these facilities have well-trained staff, advanced equipment, and established trust with pet owners, leading to higher vaccination rates.
   
• Moreover, veterinary hospitals often provide tailored vaccination schedules and recommendations based on individual pet needs, further solidifying their dominance in the market for dog vaccines.
   

The U.S. dominated the North American dog vaccine market accounting for USD 683.4 million in 2023.
 

• The U.S. boasts a large population of pet dogs with millions of households owning at least one canine companion. For instance, an article published by My Golden Retriever Puppies in August 2023, reported that dogs and cats are globally cherished and widely favored as pets, with the U.S. alone hosting an estimated 89.7 million pet dogs. This high pet ownership rate created a substantial market for dog vaccines.
   
• Also, the U.S. has a well-developed veterinary healthcare infrastructure, including veterinary clinics, hospitals, and research institutions, facilitating widespread access to vaccination services. Further, the presence of leading companies and innovative research in the U.S. also contributes to its dominance, with the country often being at the forefront of advancements in companion drug and vaccine development. Such aforementioned factor is expected to spur the country level market growth.
   

Germany exhibited a high growth potential in the European dog vaccine market.
 

• Germany plays a significant role in the European dog vaccine industry due to its extensive scientific research, innovation, and development in animal health. Germany's strong research infrastructure and regulatory environment support the development of new vaccines and ensure their safety and efficacy.
   
• Further, the country's high pet ownership rate, particularly for dogs, drives demand for dog vaccines.
   

The Asia Pacific dog vaccine market is poised for rapid growth with a CAGR of 6.3% during the forecast period.
 

• The Asia Pacific region offers substantial growth potential in the dog vaccine industry driven by increasing urbanization, higher disposable incomes, and changing lifestyles. As more households welcome dogs into their families, the demand for pet healthcare, including vaccinations, has surged.
   
• Also, government initiatives promoting responsible pet ownership and public health awareness campaigns also play a role in driving vaccine uptake. For instance, in 2022, the Brihanmumbai Municipal Corporation (BMC) partnered with Mission Rabies to pursue a rabies-free status for Mumbai, India. A pilot program in September and October inoculated over 14,000 dogs, while a 2024 drive aligns with a national initiative to eliminate rabies in India by 2030, intending to vaccinate thousands more. This collaborative effort aimed to accelerate vaccination programs is expected to supplement the market expansion.
   

Dog Vaccine Market Share

The dog vaccines industry is characterized by prominent players offering wide array of vaccines targeting various canine diseases. These companies boast established reputations and extensive distribution networks. The emerging players are gaining traction, focusing on innovative vaccine formulations and expanding their market presence. Competition is fierce, with companies competing on product efficacy, safety, pricing, and market reach. The dynamic nature of the market ensures ongoing evolution as new entrants enter and existing players innovate to maintain their competitive edge.
 

Dog Vaccine Market Companies

Some of the prominent players operating in the dog vaccine industry include:

• Bioveta, a.s.
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma
• Creative Biolabs
• Elanco Animal Health Incorporated
• Merck & Co., Inc.
• NEOTECH, LLC
• Virbac
• Zendal Group
• Zoetis Inc.
   

Dog Vaccine Industry News

• In March 2024, Merck Animal Health, collaborating with Mission Rabies, is committed to aiding the ambitious global objective of the United Against Rabies Forum, aiming for zero human deaths from dog-mediated rabies by 2030. Their contribution includes donations of NOBIVAC rabies vaccines, extending over the next five years. These donations will fulfill the annual rabies vaccine needs of the non-profit organization. This partnership underscores the dedication of both entities to combatting rabies and saving lives globally.
   
• In March 2024, Petia Vet Health, a subsidiary of the Zendal group, launched the Neoleish vaccine, the first vaccine for animal mammals based on recombinant DNA, to address canine leishmaniasis. Dedicated to pet health, Petia Vet Health will oversee the vaccine's marketing in Spain. This innovative vaccine launched marked a significant advancement in combating canine leishmaniasis and explored and opportunity in the animal healthcare sector.
   

The dog vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Live attenuated
• Inactivated
• Recombinant
• Other vaccine types

Market, By Disease Type

• Canine distemper
• Canine infectious respiratory disease complex (CIRDC)
• Canine parvovirus
• Canine leptospirosis
• Canine lyme disease
• Infectious canine hepatitis
• Canine rabies
• Other disease types

Market, By Route of Administration

• Intranasal
• Injectable
• Oral

Market, By End-use

• Veterinary hospitals
• Veterinary clinics
• Research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa